Supplements That Interact with Antidepressants: Risks & Safe Use

If you take an antidepressant, it’s smart to ask which supplements that interact with antidepressants should be avoided or used carefully. This guide explains which combinations raise risk, how interactions happen, the warning signs to know, and practical steps to stay safe—all with clear evidence levels and a balanced view of both western pharmacology and traditional use.

Quick summary — who should read this

• You take an SSRI, SNRI, MAOI, TCA, or an atypical antidepressant and are considering supplements for mood, sleep, pain, immunity, brain health, or general wellness.
• You already use supplements (like St. John’s wort, 5‑HTP, SAMe, CBD, kava, ginkgo, fish oil, turmeric) and want to check for safety with antidepressants.
• You’ve had side effects (e.g., restlessness, unusual bleeding, excessive sedation) and wonder if a supplement is involved.

Key points at a glance:

• The most clinically important risks are serotonin excess (serotonin syndrome), excessive sedation, increased bleeding risk, and changes in drug levels via liver enzymes (CYP450) or transporters (P‑glycoprotein).
• Highest‑risk pairings include MAOIs with serotonergic supplements; SSRIs/SNRIs with St. John’s wort or 5‑HTP/tryptophan/SAMe; and any sedating antidepressant with kava, valerian, or high‑dose CBD.
• Evidence strength varies: some interactions are strongly supported (e.g., St. John’s wort), while others are based on limited studies or case reports (e.g., saffron, berberine, rhodiola).

This information is educational and not a substitute for medical advice. Always discuss changes with your prescriber or pharmacist.

How antidepressants work — and which classes matter

Understanding how antidepressants act helps explain why certain supplements interact.

• SSRIs (selective serotonin reuptake inhibitors): fluoxetine, sertraline, citalopram, escitalopram, paroxetine, fluvoxamine. Increase serotonin levels. Some also affect liver enzymes; fluoxetine and paroxetine inhibit CYP2D6; fluvoxamine inhibits CYP1A2 and CYP3A4.
• SNRIs (serotonin–norepinephrine reuptake inhibitors): venlafaxine, desvenlafaxine, duloxetine, levomilnacipran. Increase serotonin and norepinephrine. Duloxetine uses CYP1A2/2D6 metabolism.
• TCAs (tricyclic antidepressants): amitriptyline, nortriptyline, imipramine, clomipramine. Affect serotonin and norepinephrine; metabolized mainly by CYP2D6. Can prolong QT interval and cause anticholinergic effects.
• MAOIs (monoamine oxidase inhibitors): phenelzine, tranylcypromine, isocarboxazid; selegiline (transdermal). Block monoamine breakdown, markedly raising serotonin, norepinephrine, dopamine—very interaction‑prone.
• Atypicals: bupropion (NDRI; strong CYP2D6 inhibitor), mirtazapine (sedating; CYP3A4 substrate), trazodone (sedating; can prolong QT), vilazodone and vortioxetine (serotonergic, CYP metabolism), and dextromethorphan–bupropion (Auvelity; serotonergic and NMDA activity).

Other drugs that behave like MAOIs (e.g., linezolid antibiotic) or serotonergic agents (e.g., triptans, tramadol, dextromethorphan) can compound risk when added to supplements.

Common supplements that can interact (what to watch and why)

Evidence level key: strong (multiple RCTs/meta‑analyses or consistent clinical data), moderate (limited RCTs/observational studies), emerging (preclinical or case reports), traditional (historical use; limited modern data).

High‑risk serotonergic supplements

• St. John’s wort (Hypericum perforatum) — Evidence: strong

  • Risks: Serotonin syndrome with SSRIs/SNRIs/MAOIs; induction of CYP3A4, CYP2C9, CYP2C19, and P‑gp can lower levels of many drugs; may precipitate hypomania in bipolar spectrum.
  • Clinical note: Potent drug–herb interactor; avoid with most antidepressants unless supervised. See our detailed guide: St. John’s Wort Interactions: Drugs, Risks, and Safety Guide.

• 5‑HTP and L‑tryptophan — Evidence: moderate (case reports, pharmacology)

  • Risks: Additive serotonin; case reports of serotonin syndrome, especially with MAOIs or high‑dose SSRIs/SNRIs; can cause GI upset and vivid dreams.

• SAMe (S‑adenosyl‑L‑methionine) — Evidence: moderate

  • Risks: Additive serotonin; case reports of agitation or mania in bipolar; theoretical risk of serotonin syndrome.
  • Potential benefit: As an adjunct, some studies suggest symptom improvement when monitored; requires prescriber oversight.

• Rhodiola rosea — Evidence: emerging

  • Risks: Mild MAO‑A inhibition proposed; case reports of agitation/insomnia and rare serotonin syndrome when combined with SSRIs.

• Saffron (Crocus sativus) — Evidence: emerging

  • Risks: Theoretical serotonergic effects; mild antiplatelet activity; limited interaction data—use caution with SSRIs/SNRIs and those at bleeding risk.

Supplements increasing bleeding risk (especially with SSRIs/SNRIs)

Platelets use serotonin for clotting; SSRIs/SNRIs reduce platelet serotonin and can modestly raise bleeding risk. Adding antiplatelet/anticoagulant supplements may compound this.

• Ginkgo biloba — Evidence: moderate

  • Risks: Antiplatelet effects; case reports of bleeding (including intracranial) with antithrombotics; combine cautiously with SSRIs/SNRIs and in people with GI bleeding risk.

• Fish oil (omega‑3 EPA/DHA) — Evidence: moderate

  • Risks: High doses may increase bleeding time; clinical bleeding risk appears low up to ~3 g/day EPA+DHA, but caution with SSRIs/SNRIs plus anticoagulants/antiplatelets.
  • Note: Some evidence supports adjunctive use for mood; coordinate with your clinician and monitor.

• Turmeric/curcumin — Evidence: moderate

  • Risks: Antiplatelet effects; may interact with anticoagulants/antiplatelets; potential CYP/P‑gp effects are inconsistent but possible. See: Does Turmeric Interact with Medications?.

• Garlic (high‑dose), vitamin E (≥400 IU), and others — Evidence: emerging to moderate

  • Risks: Additive antiplatelet/anticoagulant effects; consider avoidance or careful monitoring with SSRIs/SNRIs if you have a bleed history.

Sedating or CNS‑depressant supplements

Additive sedation can impair reaction time and increase falls, especially with mirtazapine, trazodone, TCAs, or when alcohol is used.

• Kava (Piper methysticum) — Evidence: moderate for sedation; interactions: moderate

  • Risks: Additive CNS depression; rare but serious liver toxicity; avoid with sedating antidepressants and in liver disease.

• Valerian — Evidence: moderate

  • Risks: Additive sedation with trazodone, mirtazapine, TCAs; may impair driving.

• Melatonin — Evidence: moderate

  • Risks: Generally safe, but fluvoxamine markedly increases melatonin levels (CYP1A2 interaction); additive drowsiness with sedating antidepressants.

• Magnesium (high doses), L‑theanine, and others — Evidence: emerging to moderate

  • Risks: Additive sedation/dizziness in sensitive individuals; separate magnesium from certain meds by a few hours to avoid absorption issues.

CYP450 and transporter interactions (changing antidepressant levels)

• St. John’s wort — Evidence: strong

  • Induces CYP3A4/2C9/2C19 and P‑gp; can reduce levels of many drugs (e.g., some TCAs, mirtazapine, vortioxetine) and oral contraceptives.

• CBD (cannabidiol) — Evidence: moderate

  • Inhibits CYP2C19 and CYP3A4; may raise levels of citalopram/escitalopram and some TCAs; additive sedation. Quality and dosing vary widely.

• Berberine — Evidence: emerging to moderate

  • Inhibits CYP3A4 and P‑gp; theoretical increase in levels of TCAs, mirtazapine, trazodone, vilazodone, vortioxetine; monitor for side effects.

• Grapefruit (juice/extract) — Evidence: strong (not a supplement but a common natural product)

  • Inhibits CYP3A4; may raise levels of several antidepressants (e.g., sertraline, citalopram, mirtazapine, trazodone). Avoid consistent high intake unless cleared by your clinician.

QT prolongation concerns

Some antidepressants (citalopram, escitalopram, TCAs, trazodone) can prolong the QT interval, especially at higher doses or with other QT‑prolonging agents.

• Supplements with possible QT effects: berberine (case reports, high doses), bitter orange (synephrine; stimulatory), and products adulterated with stimulants. Evidence: emerging. If you already have cardiac risk or are on QT‑prolonging meds, avoid stimulant‑type supplements and discuss berberine with your clinician.

Other notable interactions and special cases

• Ginseng — Evidence: emerging

  • Case reports of mania when combined with phenelzine (MAOI) and possible stimulant effects; use caution with any antidepressant in those with bipolar spectrum.

• Kratom — Evidence: emerging (safety concerns)

  • Opioid‑like and serotonergic properties; numerous CYP interactions; not recommended with antidepressants.

• Iron — Evidence: limited for direct antidepressant interactions

  • Not a known significant pharmacokinetic interaction with antidepressants, but can impair absorption of other meds; separate from medications by 2+ hours to minimize chelation issues.

How interactions happen (mechanisms to know)

• Serotonergic excess: Multiple serotonergic inputs (SSRI/SNRI/MAOI + 5‑HTP/tryptophan/SAMe/St. John’s wort) can trigger serotonin syndrome—a potentially life‑threatening condition.
• CYP450 and transporter changes: Induction (e.g., St. John’s wort) can lower antidepressant levels and reduce effect; inhibition (e.g., CBD, grapefruit, berberine) can raise levels and side effects.
• Bleeding risk: SSRIs/SNRIs reduce platelet serotonin; adding supplements with antiplatelet/anticoagulant effects (ginkgo, fish oil, turmeric, garlic, vitamin E) may raise bleeding risk.
• Sedation/CNS depression: Sedative supplements (kava, valerian, melatonin, magnesium) can add to drowsiness from mirtazapine, trazodone, TCAs, or alcohol.
• QT prolongation/arrhythmia risk: Additive effects with certain antidepressants and stimulant‑type botanicals or supplements with QT potential.

What the research says (evidence‑rated highlights)

• St. John’s wort interactions are well documented (strong evidence), including both serotonergic toxicity and potent CYP induction that alters many drugs.
• Serotonin syndrome cases are reported with SSRIs/SNRIs/MAOIs combined with 5‑HTP, tryptophan, SAMe, rhodiola, and St. John’s wort (moderate evidence overall, stronger for St. John’s wort).
• Additive bleeding with SSRIs/SNRIs plus ginkgo/garlic/turmeric/vitamin E is supported by pharmacology and case reports (moderate evidence); with fish oil, clinically significant bleeding appears uncommon at standard doses (moderate evidence).
• CBD can increase concentrations of citalopram/escitalopram via CYP2C19/3A4 inhibition (moderate evidence from PK studies and case series); sedation is additive.
• Kava/valerian add to CNS depression (moderate evidence); kava has rare hepatotoxicity signals.
• Fluoxetine/paroxetine inhibit CYP2D6 (strong evidence), which can raise levels of TCAs if combined; bupropion is also a strong 2D6 inhibitor, compounding this.

Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies

by Mitchell Bebel Stargrove ND LAc (Author), Jonathan Treasure MA MNIMH RH (AHG) MCPP (Author), Dwight L. McKee MD (Author) & 0 more

Check Price on Amazon

Traditional perspective: Many of these botanicals (e.g., St. John’s wort, rhodiola, saffron, ginseng, kava) have centuries of use for mood, vitality, or calm. Traditional use underscores potential efficacy, but modern drug–herb interactions can be significant, especially with concentrated extracts. When traditional remedies meet contemporary antidepressants, supervision becomes essential.

Recognizing dangerous signs and when to seek help

Call emergency services if severe or rapidly worsening symptoms occur.

• Possible serotonin syndrome: agitation, restlessness, confusion, shivering, sweating, fever, diarrhea, muscle twitching/rigidity, tremor, dilated pupils, racing heart, high blood pressure. Severe cases can cause high fever and seizures.
• Excessive bleeding: black or bloody stools, vomiting blood/coffee‑ground material, unusual nosebleeds, easy bruising, prolonged bleeding from cuts.
• Dangerous sedation or overdose‑like effects: extreme drowsiness, slowed breathing, unresponsiveness—especially with sedatives plus alcohol or opioids.
• Heart rhythm concerns: palpitations, fainting, severe dizziness—particularly if you take QT‑prolonging antidepressants.
• Mood switching: new or worsening agitation, insomnia, rapid thoughts, or euphoria that could suggest hypomania/mania, especially after starting SAMe, ginseng, or St. John’s wort.
• Liver issues (rare but important with kava or multi‑ingredient products): yellowing skin/eyes, dark urine, right‑upper‑abdomen pain, severe fatigue.

Practical steps to reduce risk

• Talk to your prescriber or pharmacist before starting, stopping, or changing any supplement. Bring bottles or a full list to visits.
• Use an interaction checker before you add anything new:
  • Drug Interaction Checker — Check Rx, OTC & Supplement Interactions
  • Supplement Interaction Checker — Check Drug & Supplement Interactions
  • For herbs in general, see: Herb-Drug Interactions: Risks, Common Examples, and How to Stay Safe
• Avoid stacking serotonergic agents. If you take an SSRI/SNRI, generally avoid St. John’s wort, 5‑HTP, L‑tryptophan, SAMe, and rhodiola unless closely supervised.
• If you take an MAOI, avoid serotonergic supplements entirely and be cautious with any stimulant or tyramine‑rich products.
• Start low and go slow with any supplement. Monitor for 1–2 weeks for side effects before adjusting.
• Separate dosing when needed: space minerals (iron, magnesium, calcium) 2–4 hours from medicines to reduce absorption issues; avoid grapefruit around meds affected by CYP3A4.
• Monitor targeted markers: if using fish oil or turmeric and you have bleed risk, ask about checking CBC or coagulation markers, especially with other blood‑thinners.
• Keep a single prescriber informed. Maintain one pharmacy when possible so interactions are flagged.
• Document changes and effects. A simple symptom and side‑effect log can help your clinician fine‑tune therapy.
• Do not abruptly stop antidepressants when adding a supplement. Antidepressant withdrawal can mimic side effects and complicate care.
• Special populations: pregnancy/breastfeeding, older adults, liver/kidney disease, and bipolar spectrum require extra caution and individualized advice.

Ezy Dose Weekly (7-Day) AM/PM Pill Organizer, Vitamin and Medicine Box, Small Pop-out Compartments, 2 Times a Day, Blue and Purple Lids

View on Amazon

Recommended product considerations (quality, testing, and thoughtful options)

Choosing well‑made products won’t eliminate interactions, but it reduces variability and contamination.

Nordic Naturals Ultimate Omega, Lemon Flavor - 180 Soft Gels - 1280 mg Omega-3 - High-Potency Fish Oil with EPA & DHA - Promotes Brain & Heart Health - Non-GMO - 90 Servings

View on Amazon

• Look for third‑party testing or certifications (USP Verified, NSF, Informed Choice, or ConsumerLab tested) and transparent labels listing standardized extracts and exact milligram amounts.
• Prefer single‑ingredient products to better track effects and avoid hidden overlaps (e.g., multiple products each containing 5‑HTP).
• Consider reputable, third‑party tested basics when appropriate and approved by your clinician:
  • Many people choose a high‑purity omega‑3 with clear EPA/DHA amounts, such as High‑Purity EPA/DHA Fish Oil. Coordinate dose and timing with your prescriber, especially if you have bleeding risk.
  • For occasional sleep support discussed with your clinician, a low‑dose, USP‑verified melatonin (e.g., 0.5–1 mg) like USP‑Verified Melatonin 1 mg can help with timing; avoid with fluvoxamine and monitor for daytime drowsiness.
  • To stay organized and reduce dosing errors, a simple Weekly Pill Organizer can be helpful.

Affiliate disclosure: If you purchase through links on our site, we may earn a commission at no additional cost to you. We only mention options we’d consider for ourselves and that align with evidence‑based practice, but this is not medical advice or an endorsement of therapeutic efficacy.

Practical takeaways

• The phrase “supplements that interact with antidepressants” covers a wide range—from well‑documented (St. John’s wort) to theoretical (some botanicals). The big four risks are serotonin overload, sedation, bleeding, and altered drug levels via CYP enzymes.
• If you take an SSRI/SNRI, be especially cautious with St. John’s wort, 5‑HTP/tryptophan, SAMe, rhodiola (serotonergic), ginkgo, turmeric, high‑dose fish oil (bleeding), kava/valerian/melatonin (sedation), and CBD/berberine/grapefruit (CYP effects).
• If you take a TCA or drugs with QT risk, be cautious with stimulant‑type products and berberine; if you take sedating antidepressants, avoid stacking with other sedatives.
• When in doubt, check interactions, start low, and keep your care team in the loop.

Additional resources

• Clinical pharmacology databases (e.g., Lexicomp, Micromedex), Natural Medicines, and Cochrane Reviews for evidence appraisals
• FDA Safety Communications for herbal product advisories and adulteration warnings
• NIH Office of Dietary Supplements fact sheets for ingredient overviews
• The Maudsley Prescribing Guidelines and APA practice guidelines for antidepressant management

Disclaimer

This article is for educational purposes only and is not a substitute for personalized medical advice. Supplements can meaningfully interact with antidepressants. Do not start, stop, or change any medication or supplement without consulting your healthcare professional. If you experience concerning symptoms (e.g., severe agitation, high fever, black stools, fainting), seek urgent medical care.